In order to extend our observations on the therapeutically potential of LDH-A inhibitors in GBM, viability experiments were repeated in different GBM cell lines, displaying either a wild-type p53 (i.e., U343MG, ANGM-CSS cells33, 34) or a mutated p53 (T98G cells35). This evidence concerns the gene TP53 and glioblastoma.